Category: 637-58-1

Popovic, Radomir published the artcileCoulometric determination of some local anesthetics, COA of Formula: C17H28ClNO3, the publication is Acta Pharmaceutica Jugoslavica (1967), 17(2), 77-80, database is CAplus.

Coulometric determination of the local anesthetics procaine-HCl, tetracaine-HCl, lignocaine-HCl, amylocaine-HCl, dibucaine-HCl, pramoxine-HCl, Panthesine-HCl, and Falicaine-HCl is proposed. After passing the solution (1%) of anesthetic through a column of Dowex 2 the effluent (5 ml.) is titrated coulometrically in the anode compartment in the presence of 10 ml. 0.01 N H2SO4 and 5 drops phenolphthalein.

Acta Pharmaceutica Jugoslavica published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, COA of Formula: C17H28ClNO3.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Wilkes, Sally R. published the artcileHow Clinically Relevant Are Treatment Comparisons of Topical Calcineurin Inhibitor Trials for Atopic Eczema?, COA of Formula: C17H28ClNO3, the publication is Journal of Investigative Dermatology (2016), 136(10), 1944-1949, database is CAplus and MEDLINE.

We sought to explore the architecture of trials of calcineurin inhibitors for atopic eczema to document the extent to which comparisons with active treatments such as topical corticosteroids might have been included or avoided. We identified all eligible randomized controlled trials using the Global Resource for EczemA Trials (GREAT) database. Network plots were produced where the nodes represented a treatment type and the lines between the nodes represented the number of trials or participants involved in the various treatment comparisons. A total of 174 randomized controlled trials for atopic eczema treatments were identified in which pimecrolimus, tacrolimus, or topical corticosteroids were compared with another intervention or a vehicle/emollient. Of 39 trials involving pimecrolimus and 41 trials involving tacrolimus, 8 (20.5%) and 13 (31.7%), resp., made comparisons with topical corticosteroids, and 25 (64.1%) and 15 (36.6%), resp., were vehicle-controlled studies. The high rate of comparisons with vehicle controls in randomized controlled trials that assessed the efficacy of pimecrolimus or tacrolimus long after efficacy had been established is a matter of concern. Active comparators (mild topical corticosteroids for pimecrolimus and moderate to potent topical corticosteroids for tacrolimus) are best placed to determine how topical calcineurin inhibitors compare with established clin. practice.

Journal of Investigative Dermatology published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C4H5F3N2O3S, COA of Formula: C17H28ClNO3.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Craviso, Gale L. published the artcileCompetitive inhibition of stereospecific opiate binding by local anesthetics in mouse brain, HPLC of Formula: 637-58-1, the publication is Life Sciences (1975), 16(12), 1803-8, database is CAplus and MEDLINE.

Cationic local anesthetics inhibited competitively the stereospecific binding of naltrexone (I) [16590-41-3] and etorphine [14521-96-1] to the mouse brain opiate receptor. In contrast, the inhibition produced by benzocaine [94-09-7], a noncationic local anesthetic, was noncompetitive. Thus, it appears that the cationic group of local anesthetics interacts with a specific anionic binding site on the opiate receptor and that there are certain structural similarities between the receptors for both types of drugs. In addition, several drugs appear to be able to unspecifically modify the pharmacol. effects of opiates and they could be useful tools to further characterize the opiate receptor.

Life Sciences published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, HPLC of Formula: 637-58-1.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Merey, Hanan A. published the artcileSimultaneous determination of pramocaine HCl and hydrocortisone acetate in pharmaceutical dosage form, Category: ethers-buliding-blocks, the publication is Journal of Liquid Chromatography & Related Technologies (2013), 36(19), 2774-2784, database is CAplus.

Two sensitive and selective methods were developed and validated for simultaneous determination of pramocaine HCl and hydrocortisone acetate in pharmaceutical dosage form. The first method is a spectrodensitometric method where pramocaine HCl and hydrocortisone acetate were separated using toluene:methanol:chloroform: 10% NH₃ [(5:3:6:0.1, by volume) as the developing system followed by densitometric measurement at 290 nm] and 250 nm for pramocaine HCl and hydrocortisone acetate, resp. The second method is a high performance liquid chromatog. method for separation and determination of both drugs using reversed phase C₁₈ column and mobile phase consisting of distilled water:acetonitrile:triethylamine (530:470:0.1, by volume); pH was adjusted to 3 by o-phosphoric acid. The proposed methods were successfully applied for the anal. of pramocaine HCl and hydrocortisone acetate in laboratory prepared mixtures and in pharmaceutical dosage form and the results obtained were assessed by applying the standard addition technique. Statistical comparison between the results obtained by applying the proposed methods and official method for the cited drugs was done and no significant difference was found at p = 0.05.

Journal of Liquid Chromatography & Related Technologies published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Category: ethers-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Ramadan, Nesrin K. published the artcileIon-selective electrodes for the potentiometric determination of pramoxine HCl using different ionophores, Computed Properties of 637-58-1, the publication is Acta Chimica Slovenica (2012), 59(4), 870-878, database is CAplus and MEDLINE.

Four novel pramoxine HCl (PAM) selective electrodes were investigated with 2-nitrophenyl octylether as a plasticizer in a polymeric matrix of polyvinyl chloride (PVC). Sensor 1 was fabricated using sodium-tetraphenylborate (TPB) as an anionic exchanger without incorporation of an ionophore. Sensor 2 used 2-hydroxy propyl-cyclodextrin as an ionophore, while sensors 3 and 4 were constructed using 4-sulfocalix-6-arene and 4-sulfocalix-8-arene, resp. as ionophores. Linear responses of PAM within the concentration ranges of 1.0 × 10^-4 to 1.0 × 10^-2 mol L^-1 and 1.0 × 10^-5 to 1.0 × 10^-2 mol L^-1 were obtained using sensors 1 and 2, resp. and 1.0 × 10^-6 to 1.0 × 10^-2 mol L^-1 were obtained using sensors 3 and 4. Nernstian slopes of 50.4, 54.3, 56.3, and 59.1 mV/decade over the pH range of 3.0-6.0 were observed The selectivity coefficients of the developed sensors indicated excellent selectivity for PAM. The utility of 2-hydroxy-Pr β-cyclodextrin (2HP-β-CD) and 4-sulfocalix [6,8] arene (SC 6,8) as ionophores had a significant influence on increasing the membrane sensitivity and selectivity of sensors 2, 3, and 4 compared to sensor 1. The proposed sensors displayed useful anal. characteristics for the determination of PAM in bulk powder, pharmaceutical formulation, and in biol. fluid. Validation of the method showed the suitability of the proposed electrodes for the use in the quality control assessment of the drug. Furthermore, statistical comparison between the results obtained by the proposed method and the official method of the drug was performed and no significant difference was found.

Acta Chimica Slovenica published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Computed Properties of 637-58-1.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Bury, Ross W. published the artcileInteractions between local anesthetics and spasmogens on the guinea-pig ileum, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is Journal of Pharmacology and Experimental Therapeutics (1976), 197(3), 633-40, database is CAplus and MEDLINE.

The effect of various local anesthetics and other substances known to modify Ca fluxes in cells, on submax. responses of guinea pig ileum to substance P [33507-63-0], acetylcholine, histamine, and BaCl2 was determined Procaine-HCl [51-05-8] caused a dose-related depression of the response to all the agonists but the response to substance P was far less susceptible to this depression. Lidocaine-HCl [73-78-9], bupivacaine-HCl [18010-40-7], pramoxine-HCl [637-58-1] and W 6211 [22759-46-2] also caused a lower degree of attenuation of the response to substance P than the responses to acetylcholine, histamine, and BaCl2. Verapamil [52-53-9] caused a dose-related depression of responses to all the agonists equally. The use of Ca-free solutions abolished responses to substance P, acetylcholine, and histamine. The response to BaCl2 was less affected by Ca withdrawal but was reduced markedly. In the presence of 10 mM LaCl, the response to all the agonists was abolished. The relative resistance of the substance P responses to antagonism by local anesthetics suggests that different and more efficient channels for Ca entry into the smooth muscle cell are involved.

Journal of Pharmacology and Experimental Therapeutics published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Weinberger, R. published the artcileHigh-pressure liquid chromatographic analysis of pramoxine hydrochloride in high lipoid aerosol foam dosage form, Related Products of ethers-buliding-blocks, the publication is Journal of Pharmaceutical Sciences (1980), 69(4), 475-7, database is CAplus and MEDLINE.

A rapid and quant. method for the determination of pramoxine-HCl (I) [637-58-1] by high-pressure liquid chromatog. is presented. The drug is extracted as the salt from a preparation with a high lipoid composition by partitioning it to the aqueous phase of an Et₂O-MeOH-H₂O-AcOH system. The extract is chromatographed on an octadecylsilane bonded packing with MeOH-H₂O-AcOH-MeSO₃H mobile phase. The time required for each separation is âˆ? min. Anal. recoveries of 100.4 ± 1.5% were obtained.

Journal of Pharmaceutical Sciences published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C9H9NO, Related Products of ethers-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Fliri, Anton F. published the artcileDrug effects viewed from a signal transduction network perspective, Related Products of ethers-buliding-blocks, the publication is Journal of Medicinal Chemistry (2009), 52(24), 8038-8046, database is CAplus and MEDLINE.

Understanding how drugs affect cellular network structures and how resulting signals are translated into drug effects holds the key to the discovery of medicines. Herein we examine this cause-effect relationship by determining protein network structures associated with the generation of specific in vivo drug-effect patterns. Medicines having similar in vivo pharmacol. have been identified by a comparison of drug-effect profiles of 1320 medicines. Protein network positions reached by these medicines were ascertained by examining the coinvestigation frequency of these medicines and 1179 protein network constituents in millions of scientific investigations. Interestingly, medicine associations obtained by comparing by drug-effect profiles mirror those obtained by comparing drug-protein coinvestigation frequency profiles, demonstrating that these drug-protein reachability profiles are relevant to in vivo pharmacol. By using protein associations obtained in these investigations and independent, curated protein interaction information, drug-mediated protein network topol. models can be constructed. These protein network topol. models reveal that drugs having similar pharmacol. profiles reach similar discrete positions in cellular protein network systems and provide a network view of medicine cause-effect relationships.

Journal of Medicinal Chemistry published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Related Products of ethers-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Varkuti, Boglarka H. published the artcileHigh-Throughput Small Molecule Screen Identifies Modulators of Mitochondrial Function in Neurons, Name: 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is iScience (2020), 23(3), 100931, database is CAplus and MEDLINE.

We developed a high-throughput assay for modulators of mitochondrial function in neurons measuring inner mitochondrial membrane potential (ΔΨ_m) and ATP production The assay was used to screen a library of small mols., which led to the identification of structural/functional classes of mitochondrial modulators such as local anesthetics, isoflavones, COXII inhibitors, adrenergic receptor blockers, and neurotransmitter system effectors. Our results show that some of the isolated compounds promote mitochondrial health, enhance oxygen consumption rate, and protect neurons against toxic insults found in the cellular environment of Alzheimer disease. These studies offer a set of compounds that may provide efficacy in protecting the mitochondrial system in neurodegenerative disorders.

iScience published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C4H8Cl2S2, Name: 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Beraki, Simret published the artcileA pharmacological screening approach for discovery of neuroprotective compounds in ischemic stroke, SDS of cas: 637-58-1, the publication is PLoS One (2013), 8(7), e69233, database is CAplus and MEDLINE.

With the availability and ease of small mol. production and design continuing to improve, robust, high-throughput methods for screening are increasingly necessary to find pharmacol. relevant compounds amongst the masses of potential candidates. Here, we demonstrate that a primary oxygen glucose deprivation assay in primary cortical neurons followed by secondary assays (i.e. post-treatment protocol in organotypic hippocampal slice cultures and cortical neurons) can be used as a robust screen to identify neuroprotective compounds with potential therapeutic efficacy. In our screen about 50% of the compounds in a library of pharmacol. active compounds displayed some degree of neuroprotective activity if tested in a pre-treatment toxicity assay but just a few of these compounds, including Carbenoxolone, remained active when tested in a post-treatment protocol. When further examined, Carbenoxolone also led to a significant reduction in infarction size and neuronal damage in the ischemic penumbra when administered six hours post middle cerebral artery occlusion in rats. Pharmacol. testing of Carbenoxolone-related compounds, acting by inhibition of 11-β-hydroxysteroid dehydrogenase-1 (11β-HSD1), gave rise to similarly potent in vivo neuroprotection. This indicates that the increase of intracellular glucocorticoid levels mediated by 11β-HSD1 may be involved in the mechanism that exacerbates ischemic neuronal cell death and inhibiting this enzyme could have potential therapeutic value for neuroprotective therapies in ischemic stroke and other neurodegenerative disorders associated with neuronal injury.

PLoS One published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, SDS of cas: 637-58-1.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem